BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33677052)

  • 1. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
    Cohen-Cutler S; Wong K; Mena V; Sianto K; Wright MA; Olch A; Orgel E
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1488-1495. PubMed ID: 33677052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.
    Paulino AC; Lobo M; Teh BS; Okcu MF; South M; Butler EB; Su J; Chintagumpala M
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1445-50. PubMed ID: 20231075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
    Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer.
    Bass JK; Hua CH; Huang J; Onar-Thomas A; Ness KK; Jones S; White S; Bhagat SP; Chang KW; Merchant TE
    J Clin Oncol; 2016 Apr; 34(11):1248-55. PubMed ID: 26811531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors.
    Merchant TE; Gould CJ; Xiong X; Robbins N; Zhu J; Pritchard DL; Khan R; Heideman RL; Krasin MJ; Kun LE
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1194-207. PubMed ID: 15001264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
    Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
    Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
    Vieira WA; Weltman E; Chen MJ; da Silva NS; Cappellano AM; Pereira LD; Gonçalves MI; Ferrigno R; Hanriot RM; Nadalin W; Odone Filho V; Petrilli AS
    Radiat Oncol; 2014 Jul; 9():158. PubMed ID: 25041714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.
    Huang E; Teh BS; Strother DR; Davis QG; Chiu JK; Lu HH; Carpenter LS; Mai WY; Chintagumpala MM; South M; Grant WH; Butler EB; Woo SY
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):599-605. PubMed ID: 11849779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
    Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
    Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensorineural Hearing Loss in Nasopharyngeal Carcinoma Survivors in the Modern Treatment Era - The Early and Late Effects of Radiation and Cisplatin.
    Yip PL; Mok KCJ; Ho HS; Lee WYV; Wong ACL; Lau CT; Wong FCS; Yeung KW; Lee SF
    Clin Oncol (R Coll Radiol); 2022 Apr; 34(4):e160-e167. PubMed ID: 34772581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
    Waissbluth S; Del Valle Á; Chuang A; Becker A
    Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
    Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
    Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are There Cochlear Dead Regions Involved in Hearing Loss after Cisplatin Ototoxicity?
    Schultz C; Pecora Liberman PH; Schmidt Goffi-Gomez MV
    Audiol Neurootol; 2019; 24(5):253-257. PubMed ID: 31661686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group.
    Knight KR; Chen L; Freyer D; Aplenc R; Bancroft M; Bliss B; Dang H; Gillmeister B; Hendershot E; Kraemer DF; Lindenfeld L; Meza J; Neuwelt EA; Pollock BH; Sung L
    J Clin Oncol; 2017 Feb; 35(4):440-445. PubMed ID: 27937095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer.
    Bass JK; Liu W; Banerjee P; Brinkman TM; Mulrooney DA; Gajjar A; Pappo AS; Merchant TE; Armstrong GT; Srivastava D; Robison LL; Hudson MM; Krull KR
    JAMA Oncol; 2020 Sep; 6(9):1363-1371. PubMed ID: 32729886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy.
    Moeller BJ; Chintagumpala M; Philip JJ; Grosshans DR; McAleer MF; Woo SY; Gidley PW; Vats TS; Mahajan A
    Radiat Oncol; 2011 Jun; 6():58. PubMed ID: 21635776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
    J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
    Scobioala S; Parfitt R; Matulat P; Kittel C; Ebrahimi F; Wolters H; Am Zehnhoff-Dinnesen A; Eich HT
    Strahlenther Onkol; 2017 Nov; 193(11):910-920. PubMed ID: 28887665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.